- Home
- HAE vs VKTX Comparison
HAE vs VKTX Comparison
Compare HAE & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HAE
- VKTX
- Stock Information
- Founded
- HAE 1971
- VKTX 2012
- Country
- HAE United States
- VKTX United States
- Employees
- HAE N/A
- VKTX N/A
- Industry
- HAE Medical/Dental Instruments
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- HAE Health Care
- VKTX Health Care
- Exchange
- HAE Nasdaq
- VKTX Nasdaq
- Market Cap
- HAE 3.6B
- VKTX 3.4B
- IPO Year
- HAE 1991
- VKTX 2015
- Fundamental
- Price
- HAE $62.98
- VKTX $34.07
- Analyst Decision
- HAE Strong Buy
- VKTX Strong Buy
- Analyst Count
- HAE 9
- VKTX 14
- Target Price
- HAE $103.56
- VKTX $97.29
- AVG Volume (30 Days)
- HAE 1.4M
- VKTX 4.8M
- Earning Date
- HAE 02-06-2025
- VKTX 02-05-2025
- Dividend Yield
- HAE N/A
- VKTX N/A
- EPS Growth
- HAE 3.20
- VKTX N/A
- EPS
- HAE 2.54
- VKTX N/A
- Revenue
- HAE $1,373,515,000.00
- VKTX N/A
- Revenue This Year
- HAE $7.56
- VKTX N/A
- Revenue Next Year
- HAE $3.13
- VKTX $986.87
- P/E Ratio
- HAE $24.76
- VKTX N/A
- Revenue Growth
- HAE 8.14
- VKTX N/A
- 52 Week Low
- HAE $58.80
- VKTX $28.64
- 52 Week High
- HAE $97.97
- VKTX $99.41
- Technical
- Relative Strength Index (RSI)
- HAE 38.28
- VKTX 51.41
- Support Level
- HAE $58.80
- VKTX $28.90
- Resistance Level
- HAE $65.15
- VKTX $34.37
- Average True Range (ATR)
- HAE 2.76
- VKTX 2.37
- MACD
- HAE 0.34
- VKTX 0.66
- Stochastic Oscillator
- HAE 32.85
- VKTX 70.06
About HAE Haemonetics Corporation
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.